Evidence map›Paper›PMID 32019330›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

lncRNA ROR Promotes Gastric Cancer Drug Resistance.

Shuai Wang, Wujun Chen, Hualong Yu, Zhengming Song, Qian Li, Xin Shen, Yudong Wu, Lei Zhu, Qingxia Ma, Dongming Xing

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. The role of curcumin in modulating circular RNAs and long non-coding RNAs in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  5. Review
  6. Review
  7. siRNA-based strategies to combat drug resistance in gastric cancer.Medical oncology (Northwood, London, England) · 2024
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Shuai WangCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Wujun ChenCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Hualong YuDepartment of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Zhengming SongCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Qian LiCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Xin ShenCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yudong WuCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Lei ZhuCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Qingxia MaInnovative Drug Research and transformation platform, Qingdao Cancer Institute, Qingdao, Shandong, China.
Dongming XingCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.ORCID https://orcid.org/0000-0001-7427-0861
Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveGastric cancer is one of the most common malignant tumors worldwide, and for resectable tumors, the most effective treatment is surgery with chemotherapy in neoadjuvant or adjuvant setting. However, the majority of patients fail to achieve the ideal initial response and/or develop resistance to chemotherapy. It was reported that long noncoding RNA regulator of reprogramming (ROR) is highly associated with the progression of gastric cancer. However, the role ROR in multidrug resistance (MDR) remains unclear.

methodsThe messenger RNA levels of 63 specimens of patients with gastric cancer were determined by real-time polymerase chain reaction analysis and were correlated with drug resistance and survival of patients. To determine the cellular functions of ROR, we generated gastric cancer MDR cells. The effect of ROR depletion on multidrug resistance-associated protein 1 (MRP1) expression and cell apoptosis were examined by immunoblotting analyses, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and flow cytometry.

resultsWe found that ROR expression levels are positively associated with increased MDR and poor prognosis of patients with gastric cancer. Regulator of reprogramming expression is increased in gastric cancer cells resistant to adriamycin (ADR) and vincristine (VCR). Depletion of ROR reduced MRP1 expression and increased apoptosis of drug-resistant gastric cancer cells in response to ADR and VCR treatment.

conclusionsWe demonstrated that ROR expression promotes MRP1 expression and MDR of gastric cancer cells and is correlated with increased MDR and poor prognosis of patients with gastric cancer. Our finding highlighted the potential of targeting ROR to improve the efficacy of chemotherapy.

Indexed as

Cell Culture TechniquesCell Line, TumorDrug Resistance, NeoplasmHumansMiddle AgedRNA, Long NoncodingStomach NeoplasmsRNA, Long Noncodinggastric cancerlncRNAMDRMRP1ROR

Identifiers

PMID32019330
PMCPMC7003177
OpenAlexW3005354171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.